About Replimune
Replimune is a company based in Oxford (United Kingdom) founded in 2015 by Philip Astley-Sparke. Replimune has raised $87 million across 3 funding rounds from investors including Atlas Venture, SVB Securities and Foresite Capital. The company has 479 employees as of March 31, 2024. Replimune offers products and services including Oncolytic Immunotherapies and Investigational Therapies. Replimune operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Oxford, United Kingdom
- Employees 479 as on 31 Mar, 2024
- Founders Philip Astley-Sparke
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Replimune Group, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$247.3 M (USD)-14.6as on Mar 31, 2025
-
EBITDA
-$259.9 M (USD)-11.05as on Mar 31, 2025
-
Total Equity Funding
$87 M (USD)
in 3 rounds
-
Latest Funding Round
$55 M (USD), Series B
Sep 07, 2017
-
Investors
Atlas Venture
& 7 more
-
Employee Count
479
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Replimune
Replimune is a publicly listed company on the NASDAQ with ticker symbol REPL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Replimune
Replimune offers a comprehensive portfolio of products and services, including Oncolytic Immunotherapies and Investigational Therapies.
Therapies designed to kill tumors and enhance immune responses against cancer.
Agents for treating solid tumor cancers in trials as single or combined options.
People of Replimune
Unlock access to complete
Unlock access to complete
Funding Insights of Replimune
Replimune has successfully raised a total of $87M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $55 million completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Replimune
Replimune has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Atlas Venture, SVB Securities and Foresite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked | |
|
Venture capital firm focused on lifescience and healthcare sectors
|
Locked | Locked | Locked |
Investor details for Replimune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Replimune
Investment portfolio details for Replimune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Replimune
Detailed financials for Replimune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Replimune Comparisons
Peer comparison for Replimune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Replimune
Replimune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Replimune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Replimune
Complete news archive for Replimune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Replimune
Replimune was founded in 2015.
Replimune is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Philip Astley-Sparke is the current CEO of Replimune. They have also founded this company.
Replimune is a funded company, having raised a total of $87M across 3 funding rounds to date.
As of Mar 31, 2024, the latest employee count at Replimune is 479.
Replimune was founded in 2015 in Oxford, United Kingdom, as a biotechnology company focused on oncolytic immunotherapies. A pipeline is being developed to strengthen direct anti-tumor effects via selective virus replication and to amplify immune reactions against released tumor antigens. Programs are advanced through clinical trials, with early integration of checkpoint blockade planned. Operations center on oncology, aiming for rapid progression in therapeutic development.
Replimune's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Replimune offers Oncolytic Immunotherapies and Investigational Therapies.
Yes, Replimune is publicly traded on NASDAQ under the ticker symbol REPL.
Replimune has 8 investors. Key investors include Atlas Venture, SVB Securities, Foresite Capital, Redmile Group, and Forbion.
The ticker symbol of Replimune is REPL on NASDAQ.